PENELOPE: TAR-200 Shows Deeper Tissue Penetration vs Standard Intravesical Therapy

7 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Sia Daneshmand, MD, discusses the key findings from the PENELOPE study he presented at the SUO 2024 Annual Meeting, which evaluated the tissue penetration of gemcitabine metabolites delivered via the TAR-200 device compared to standard intravesical installation. He explains how TAR-200 achieves sustained drug release for up to 96 hours, delivering active metabolites into deeper bladder tissue layers. Dr. Daneshmand highlights the potential clinical advantages of TAR-200, particularly in addressing high-risk or BCG-unresponsive non-muscle-invasive bladder cancer. He also explores the next steps in TAR-200's development, its role in ongoing clinical trials, and future research directions aimed at optimizing its use in bladder cancer treatment.

#bladdercancer #urology #urooncology #oncology #healthcare
Category
Urology
Be the first to comment

Up Next